Navigation Links
Omeros Corporation Reports First Quarter 2013 Financial Results
Date:5/10/2013

mary safety data expected to support the initiation of OMS721 clinical studies in mid-year 2013. The pharmacokinetic results in primates demonstrated that subcutaneous administration of OMS721 resulted in maximal inhibition of the lectin pathway within six hours of administration and maintained it for two or more weeks. In addition, the bioavailability and pharmacokinetics observed in both species are expected to support subcutaneous administration in patients at a frequency of once weekly, bi-monthly or possibly at even longer intervals.
  • Announced the successful completion of the 90-day safety database lock in the second of Omeros' two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros intends to submit a New Drug Application for OMS302 to the U.S. Food and Drug Administration this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.
  • Reported that its proprietary Cellular Redistribution Assay technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G protein-coupled receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad range of disorders, having been linked to various types of cancer (e.g., breast, brain, prostate, kidney, liver, pancreatic and gastrointestinal); multiple sclerosis, attention deficit-hyperactivity, learning and memory impairments, depression and other neuropsychiatric disorders; multiple metabolic disorders including diabetes and obesity; immunologic disorders; osteoporosis and i
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
    3. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
    4. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
    5. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
    6. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
    7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
    8. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
    9. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
    10. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
    11. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    (Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    ... , , ... Orphan Drug Designation , SILVER SPRING, Md., Dec. 23 ... more transparent and accessible, the FDA has scheduled a series of ... unfamiliar with the process. The FDA can grant a special status, ...
    ... , , PHILADELPHIA, Dec. 23 URL Pharma today announced ... initiative designed to save patients money on their health insurance co-payment ... no more than $25 for a Colcrys prescription, which equates to ... the prevention and treatment of gout flares and for the treatment ...
    Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 3URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 4
    (Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
    (Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
    (Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
    (Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
    (Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
    Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
    ... MADISON, Wis., and BIRMINGHAM, Ala., Sept. 14 ... is now offering a specialized,professional liability program ... being made available through Physicians Insurance Company,of ... "We are pleased to have the ...
    ... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...
    ... STAUNTON, Va., Sept. 14 Michael Bond has,been ... joins,the company following nearly 30 years in various ... Director of Blade Process,Engineering. Bond has a wealth ... advancement of leading edge technologies for,IncisionTech and Specialty ...
    ... Sept. 14 Stryker,Corporation (NYSE: SYK ) announced ... September 25, 2007 - 4:30 p.m. Eastern Time ... New York A simultaneous webcast of the Company,s ... via the For Investors page. The,presentation for the ...
    ... Sept. 14 Most people looking for tax advice,usually ... usually see,mechanics, right? Here,s more on a new report ... and questions are actually not seeing the pros,trained in ... at:, http://media.medialink.com/WebNR.aspx?story=33829 Registered journalists can access video, ...
    ... Mylan Laboratories Inc.,(NYSE: MYL ) today announced ... of Senior Vice President and Chief Compliance Officer. ... where she was,Director of Compliance for Latin America, ... for all compliance-related matters in those,regions. Prior to ...
    Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2
    ... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
    ... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
    ... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
    ... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
    Medicine Products: